Browsing by Author : Lai, Michelle

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 1 to 14 of 14

This table browses all dspace content
Issue DateTitleJournal Title
2026A Novel Risk Prediction Model for Hepatocellular Carcinoma in MASLD: A Multinational, Multicenter Cohort StudyCLINICAL GASTROENTEROLOGY AND HEPATOLOGY
2025acFibroMASH Index for the Diagnosis of Fibrotic MASH and Prediction of Liver-related Events: An International Multicenter StudyCLINICAL GASTROENTEROLOGY AND HEPATOLOGY
2025Association between longitudinal weight change and clinical outcome in individuals with MASLDHEPATOLOGY
2025Cardiovascular-kidney-metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLDHEPATOLOGY
2026Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLDCLINICAL GASTROENTEROLOGY AND HEPATOLOGY
2026Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLDJOURNAL OF HEPATOLOGY
2026Fibrotic MASH resolutionVCTE index to diagnose fibrotic MASH resolution and predict LREs: A global multicenter studyMED(Med (New York, N.Y.))
2025From "Burnt-Out" to "Burning-Out": Capturing Liver Fat Loss in Patients With Advanced Metabolic Dysfunction-Associated Steatotic Liver Disease From a Dynamic PerspectiveGASTROENTEROLOGY
2025Head-to-head comparison between vibration-controlled transient elastography and histology in predicting liver-related events due to metabolic dysfunction-associated steatotic liver diseaseHEPATOLOGY
2026Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement CLINICAL AND MOLECULAR HEPATOLOGY
2026Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLDCLINICAL GASTROENTEROLOGY AND HEPATOLOGY
2025Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver diseaseGUT
2025Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver diseaseJOURNAL OF HEPATOLOGY
2026Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetesGUT
1

Browse

Links